<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c); Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c); Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2020-08-19 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA) is announcing the availability of a final guidance for industry entitled "Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c)." This guidance describes FDA's policy concerning the conditions under which the Agency generally does not intend to take regulatory action against an applicant or a contract research organization (CRO) that retains less than the quantity of reserve samples (that is, sample...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2020-17798</p>
    <p><strong>Publication Date:</strong> 2020-08-19</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2020/08/19/2020-17798/compliance-policy-for-the-quantity-of-bioavailability-and-bioequivalence-samples-retained-under-21">https://www.federalregister.gov/documents/2020/08/19/2020-17798/compliance-policy-for-the-quantity-of-bioavailability-and-bioequivalence-samples-retained-under-21</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2020-17798</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
